Iscalimab Biosimilar – Anti-CD40, TNFRSF5 mAb – Research Grade

Description of Iscalimab Biosimilar - Anti-CD40, TNFRSF5 mAb - Research Grade

I.

Introduction

II.

Structure of Iscalimab Biosimilar

III.

Mechanism of Action

IV.

Therapeutic Target: CD40 V. Clinical Applications

VI.

Conclusion

I.

Introduction

Iscalimab Biosimilar is a novel therapeutic antibody that targets CD40, a protein found on the surface of immune cells. This biosimilar is designed to mimic the function of an existing monoclonal antibody, TNFRSF5 mAb, which is used in the treatment of autoimmune diseases. In this article, we will delve into the structure, mechanism of action, and clinical applications of Iscalimab Biosimilar.

II.

Structure of Iscalimab Biosimilar

Iscalimab Biosimilar is a monoclonal antibody, meaning it is produced by a single clone of cells. It is a humanized antibody, which means it contains both human and non-human components. The antibody is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a variable region. The variable regions are responsible for binding to the target protein, CD40.

III.

Mechanism of Action

Iscalimab Biosimilar works by binding to CD40 on the surface of immune cells, specifically B cells and dendritic cells. This binding prevents the interaction between CD40 and its ligand, CD154, which is crucial for the activation of immune cells. By blocking this interaction, Iscalimab Biosimilar inhibits the activation and proliferation of B cells, as well as the maturation and activation of dendritic cells. This ultimately leads to a decrease in the production of pro-inflammatory cytokines and antibodies, thus reducing the symptoms of autoimmune diseases.

IV.

Therapeutic Target: CD40

CD40 is a protein belonging to the tumor necrosis factor receptor superfamily. It is primarily expressed on the surface of immune cells, including B cells, dendritic cells, and macrophages. CD40 plays a critical role in regulating the immune response by promoting the activation and differentiation of immune cells. However, in autoimmune diseases, the overactivation of CD40 signaling can lead to excessive inflammation and tissue damage. Therefore, CD40 has been identified as a therapeutic target for the treatment of autoimmune diseases.

V. Clinical Applications

Iscalimab Biosimilar is currently being investigated for the treatment of various autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. In a phase II clinical trial for rheumatoid arthritis, Iscalimab Biosimilar showed promising results in reducing disease activity and improving symptoms. It is also being studied in combination with other therapies, such as methotrexate, to enhance its efficacy.

VI.

Conclusion

In conclusion, Iscalimab Biosimilar is a novel therapeutic antibody that targets CD40, a protein involved in the pathogenesis of autoimmune diseases. Its unique mechanism of action and promising results in clinical trials make it a potential treatment option for various autoimmune diseases. Further research and clinical trials are needed to fully understand the efficacy and safety of this biosimilar.

Iscalimab Biosimilar - Anti-CD40, TNFRSF5 mAb binds to CD40 Recombinant Protein in indirect ELISA Assay

Immobilized CD40 Recombinant Protein (cat. No.PX-P4082) at 0.5µg/mL (100µL/well) can bind to Iscalimab Biosimilar - Anti-CD40, TNFRSF5 mAb (cat. No.PX-TA1503) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450